Title: Critically Appraising the Evidence for a Viral Etiology of Human

Cervical Cancer

ABSTRACT
Cervical cancer is a major public health concern, causing significant morbidity
and mortality worldwide. Over the years, there has been a growing body of
evidence suggesting a viral etiology, particularly human papillomavirus (HPV),
in the development of cervical cancer. This term paper critically appraises the
evidence for a viral etiology of human cervical cancer, focusing on the role of
HPV and its subtypes, their mechanisms of oncogenesis, epidemiological
associations, and the impact of HPV vaccination programs. By exploring these
aspects, this paper aims to provide a comprehensive understanding of the viral
factors contributing to cervical cancer and the implications for prevention and
management.
 INTRODUCTION
CERVICAL CANCER IN HUMANS: AN OVERVIEW

Cervical cancer is a significant public health concern that predominantly affects

women. It is the fourth most common cancer among women worldwide and a
leading cause of cancer-related deaths (Arbyn et al., 2020). This type of cancer
originates in the cervix, the lower part of the uterus, and can be highly invasive
if not detected and treated in its early stages.
Cervical cancer ranks as the fourth most common cancer among women
worldwide, with an estimated 604,000 new cases and 341,000 deaths in 2020
(WHO, 2020). In recent decades, there has been a paradigm shift in
understanding the etiology of cervical cancer, with a significant focus on the
role of viruses, particularly the human papillomavirus (Arbyn et al., 2020).
Etiology and Risk Factors
Cervical cancer is primarily associated with the persistent infection of high-risk
types of the human papillomavirus (HPV). HPV is a sexually transmitted virus
responsible for nearly all cases of cervical cancer (Bosch et al., 2002). Other
risk factors that contribute to the development of cervical cancer include
smoking, immunosuppression, early sexual activity, multiple sexual partners,
and poor access to healthcare and screening services (Plummer et al., 2003).
Early Detection and Screening
Cervical cancer is often preventable and highly treatable when detected at an
early stage. Screening methods such as Pap smears and HPV tests are crucial in
identifying precancerous lesions or early-stage cancer (Arbyn et al., 2018).
Timely screening and follow-up can lead to the removal of these lesions or the
early treatment of cancer, significantly reducing mortality.
Clinical Presentation and Symptoms
In its early stages, cervical cancer may be asymptomatic. As it progresses,
women may experience symptoms such as abnormal vaginal bleeding (between
periods, after intercourse, or after menopause), pain during intercourse, and
unusual vaginal discharge. These symptoms should prompt further evaluation
by a healthcare professional.
Diagnosis and Staging
The diagnosis of cervical cancer involves a thorough gynecological
examination, imaging studies (e.g., MRI, CT scans), and biopsy for histological
confirmation. Staging is crucial to determine the extent of the disease and to
guide treatment decisions. The International Federation of Gynecology and
Obstetrics (FIGO) system is commonly used for staging cervical cancer.
Treatment
The treatment of cervical cancer depends on the stage at which it is diagnosed.
Early-stage cervical cancer may be treated with surgery, including hysterectomy
or minimally invasive procedures. For more advanced stages, treatments such as
radiation therapy, chemotherapy, or a combination of these modalities are used
(NCCN, 2021).
Prevention and Vaccination
The development and widespread use of HPV vaccines have been instrumental
in preventing cervical cancer. HPV vaccines, such as Gardasil and Cervarix,
target the most common high-risk HPV types (Drolet et al., 2015). Vaccination
is recommended for both young females and males to reduce the risk of HPV
transmission and cervical cancer.
Prognosis and Survival Rates
The prognosis of cervical cancer depends on the stage at diagnosis. When
detected early, the five-year survival rate is high. However, advanced stages are
associated with poorer outcomes (NCCN, 2021). Regular screenings and early
interventions are crucial for improving survival rates.
ETIOLOGY OF CERVICAL CANCER: UNDERSTANDING THE
PRIMARY CAUSE AND CONTRIBUTING FACTORS
Cervical cancer is primarily caused by the persistent infection of certain high-
risk types of the human papillomavirus (HPV). HPV is a diverse group of
double-stranded DNA viruses that infect the squamous epithelial cells of the
cervix and other mucous membranes. Among the numerous HPV types, a subset
is classified as high-risk, with HPV-16 and HPV-18 being the most prominent
culprits (Bosch et al., 2002).
1. HPV as the Central Etiological Factor
High-risk HPV types are considered the necessary cause of cervical cancer. The
viral DNA integrates into the host genome, leading to the overexpression of
viral oncogenes, E6 and E7. These oncoproteins are central to the process of
oncogenesis. E6 binds to and degrades the tumor suppressor protein p53,
inhibiting the host cell's ability to control DNA damage and mutations
(Scheffner et al., 1990). On the other hand, E7 protein binds to and inactivates
the retinoblastoma protein (pRb), disrupting the normal cell cycle control
(Dyson et al., 1989). This disruption results in uncontrolled cell growth and the
formation of precancerous or cancerous lesions.
2. Epidemiological Associations
Epidemiological evidence has consistently supported the connection between
high-risk HPV infection and cervical cancer. Studies such as the landmark
research by Bosch et al. (2002) revealed that women infected with high-risk
HPV types have a significantly higher risk of developing cervical cancer
compared to those without HPV infection. Further evidence comes from studies
where HPV DNA and proteins have been detected in almost all cervical cancer
cases, providing strong evidence of a viral etiology (Walboomers et al., 1999).
3. Viral Persistence and Progression
High-risk HPV infection is typically transient, and in most cases, the immune
system effectively clears the virus. However, in a subset of individuals, the
virus persists, and if not effectively managed, it can lead to the development of
precancerous lesions, such as cervical intraepithelial neoplasia (CIN). Over
time, these CIN lesions can progress to invasive cervical cancer.
4. Risk Factors and Other Influences
While HPV infection is the primary cause of cervical cancer, other factors can
influence its development. Smoking, for example, is a well-established risk
factor that can interact with HPV to increase the likelihood of cervical cancer
(Plummer et al., 2003). Immunosuppression, whether due to medical conditions
or medication, can also hinder the body's ability to clear HPV infections,
increasing the risk of progression to cervical cancer.

THE ROLE OF HUMAN PAPILLOMAVIRUS (HPV):

HPV is a group of DNA viruses that infect the epithelial cells of the skin and
mucous membranes. Over 200 HPV types have been identified, and some of
them are classified as high-risk (e.g., HPV-16, HPV-18) due to their association
with cervical cancer (Doorbar et al., 2015).
Mechanisms of Oncogenesis:
HPV is believed to initiate and promote cervical cancer through several
mechanisms. High-risk HPV types can integrate into the host genome, leading
to the overexpression of viral oncogenes E6 and E7. These proteins disrupt the
normal cell cycle regulation by inactivating the tumor suppressors p53 and Rb,
respectively, leading to uncontrolled cell growth (McLellan et al., 2019).
Epidemiological Associations:
Epidemiological studies have consistently demonstrated a strong association
between high-risk HPV infection and cervical cancer. Persistent infection with
high-risk HPV types is considered the primary risk factor for cervical cancer
development(Bosch et al., 2002). Furthermore, HPV DNA and proteins have
been detected in nearly all cervical cancer cases, providing substantial evidence
of a viral etiology (Walboomers et al., 1999).

Impact of HPV Vaccination:

The introduction of HPV vaccines has significantly influenced the incidence of
cervical cancer. These vaccines target the most common high-risk HPV types
and have shown remarkable efficacy in preventing infections. As a result,
several countries have implemented HPV vaccination programs, which have led
to a decline in the prevalence of these viral infections (Drolet et al., 2015).

CRITIQUES AND CONTROVERSIES:

While the evidence for the viral etiology of cervical cancer is compelling, there
are still some critiques and controversies:
Non-HPV Factors: Other risk factors, such as smoking, sexual behavior, and
immune status, also contribute to cervical cancer. The interaction of these
factors with HPV needs further investigation (Plummer et al., 2003).
Variability in HPV Types: The contribution of specific HPV types may vary
geographically, and not all HPV types are included in the current vaccines
(Bray et al., 2012).
Cervical Cancer in HPV-Negative Cases: A small proportion of cervical
cancer cases are HPV-negative, suggesting that other factors may play a role
(Castle et al., 2002).
Effectiveness of Vaccination: The impact of HPV vaccination programs on
cervical cancer incidence and mortality may take several years to become
evident (Markowitz et al., 2020).

WORLD HEALTH ORGANIZATION RECCOMMENDATIONS

As of my last knowledge update in September 2021, the World Health
Organization (WHO) has provided several key recommendations related to
cervical cancer prevention and control. It's important to note that WHO
guidelines and recommendations may have been updated since then. I
recommend checking the most recent WHO guidelines for the latest
information. Here are some of the key recommendations related to cervical
cancer:
1. HPV Vaccination:
WHO recommends HPV vaccination as a primary prevention strategy for
cervical cancer. The vaccination is typically targeted at adolescent girls but may
also be offered to boys.
2. Screening and Early Detection:
Regular screening and early detection of precancerous lesions are crucial in
reducing the burden of cervical cancer. WHO recommends screening through
Pap smears or HPV testing, depending on the available resources and healthcare
infrastructure.
3. Accessible Screening and Treatment:
WHO emphasizes the importance of making screening and treatment services
accessible and affordable, particularly in low- and middle-income countries.
4. Cervical Cancer Treatment:
WHO recommends that all women diagnosed with cervical cancer should have
access to appropriate treatment and care, including surgery, radiation therapy,
and chemotherapy, as per the stage of the disease.
5. Integration of Services:
WHO encourages the integration of cervical cancer prevention and control
programs into broader sexual and reproductive health services to reach a wider
population.
6. Education and Awareness:
Raising awareness about cervical cancer and its prevention is crucial. WHO
recommends health education and public awareness campaigns to inform
communities about the importance of vaccination, screening, and early
treatment.

7. Monitoring and Evaluation:

WHO recommends that countries establish systems for monitoring and
evaluating the impact of cervical cancer prevention and control programs to
ensure effectiveness.
8. Reducing Disparities:
Efforts should be made to reduce disparities in cervical cancer prevention and
control. This includes addressing barriers to access to healthcare services,
particularly for marginalized and underserved populations.
Please note that the above recommendations are based on information available
as of September 2021. It is essential to refer to the most up-to-date WHO
guidelines and recommendations, as guidelines can change over time based on
new research and evolving public health strategies.

CONCLUSION
Cervical cancer is a preventable and treatable disease, primarily linked to HPV
infection. Regular screening, vaccination, and awareness are essential in
reducing its burden. Advances in early detection and treatment options have
improved the outlook for individuals affected by cervical cancer, emphasizing
the importance of early intervention and prevention.
There is substantial evidence supporting a viral etiology of human cervical
cancer, primarily driven by high-risk HPV types. The mechanisms of
oncogenesis, epidemiological associations, and the success of HPV vaccination
programs all point to the crucial role of HPV in cervical cancer. However, it is
essential to acknowledge the role of other factors and remain vigilant in
monitoring the long-term effectiveness of vaccination programs. Understanding
the viral etiology of cervical cancer is paramount for effective prevention and
management, emphasizing the importance of public health measures, including
vaccination, screening, and education.
Cervical cancer's etiology is primarily rooted in the persistent infection of high-
risk HPV types. The mechanisms by which these viruses disrupt the host cell's
natural control mechanisms and promote uncontrolled growth are well-
established. While HPV vaccination and screening programs have been
instrumental in reducing the burden of cervical cancer, understanding the
complex interplay of risk factors and other influences remains critical to
comprehensive prevention and management.

REFERENCES
Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., ...
& Bray, F. (2020). Estimates of incidence and mortality of cervical
cancer in 2018: a worldwide analysis. The Lancet Global Health, 8(2),
e191-e203.
Doorbar, J., Quint, W., Banks, L., Bravo, I. G., Stoler, M., Broker, T. R., &
Stanley, M. A. (2015). The biology and life-cycle of human
papillomaviruses. Vaccine, 30(5), F55-F70.
McLellan, A. D., Wheeler, C. M., Feldman, S., & Wang, D. (2019). DNA
vaccines for human papillomavirus-associated cancers. Recent Results in
Cancer Research, 214, 229-248.
Bosch, F. X., Lorincz, A., Muñoz, N., Meijer, C. J., & Shah, K. V. (2002). The
causal relation between human papillomavirus and cervical cancer.
Journal of Clinical Pathology, 55(4), 244-265.
Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A.,
Shah, K. V., ... & Meijer, C. J. (1999). Human papillomavirus is a
necessary cause of invasive cervical cancer worldwide. The Journal of
Pathology, 189(1), 12-19.
Drolet, M., Bénard, É., Boily, M. C., Ali, H., Baandrup, L., Bauer, H., ... &
Brisson, M. (2015). Population-level impact and herd effects following
human papillomavirus vaccination programs: a systematic review and
meta-analysis. The Lancet Infectious Diseases, 15(5), 565-580.
Plummer, M., Peto, J., Franceschi, S., & International Collaboration of
Epidemiological Studies of Cervical Cancer (2003). Time since first
sexual intercourse and the risk of cervical cancer. International Journal of
Cancer, 105(2), 204-209.
Bray, F., Lortet-Tieulent, J., Znaor, A., Brotons, M., Poljak, M., Arbyn, M., &
Ferlay, J. (2012). Patterns and trends in human papillomavirus-related
diseases in Central and Eastern Europe and Central Asia. Vaccine, 30,
F84-F90.
Castle, P. E., Wacholder, S., Sherman, M., Lorincz, A. T., Glass, A. G., &
Scott, D. R. (2002). Absolute risk of a subsequent abnormal pap among
oncogenic human papillomavirus DNA-positive, cytologically negative
women. Cancer, 95(11), 2145-2151.
Markowitz, L. E., Naleway, A. L., Klein, N. P., Lewis, R. M., Crane, B.,
Querec, T., ... & Donahue, J. G. (2020). Human papillomavirus vaccine
effectiveness against HPV infection: Evaluation of one, two, and three
doses. The Journal of Infectious Diseases, 221(6), 910-918.
Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., ...
& Bray, F. (2020). Estimates of incidence and mortality of cervical
cancer in 2018: a worldwide analysis. The Lancet Global Health, 8(2),
e191-e203.
Bosch, F. X., Lorincz, A., Muñoz, N., Meijer, C. J., & Shah, K. V. (2002). The
causal relation between human papillomavirus and cervical cancer.
Journal of Clinical Pathology, 55(4), 244-265.
Plummer, M., Peto, J., Franceschi, S., & International Collaboration of
Epidemiological Studies of Cervical Cancer (2003). Time since first
sexual intercourse and the risk of cervical cancer. International Journal of
Cancer, 105(2), 204-209.
Arbyn, M., Smith, S. B., Temin, S., Sultana, F., Castle, P., & Team, W. L. A. C.
C. E. W. G. (2018). Detecting cervical precancer and reaching
underscreened women by using HPV testing on self samples: updated
meta-analyses. BMJ, 363, k4823.
National Comprehensive Cancer Network (NCCN). (2021). NCCN Clinical
Practice Guidelines in Oncology (NCCN Guidelines): Cervical Cancer.
Version 3.2021.
"WHO Disease and injury country estimates". World Health Organization.
2009. Archived from the original on 11 November 2009. Retrieved 11
November 2009.

"WHO Fact Sheet on HPV and Cervical Cancer". World Health Organization.
24 January 2018. Retrieved 4 June 2019.

"WHO Fact Sheet on HPV and Cervical Cancer” CONTROVERSIES AND

OCTATE BILLINGS. World Health Organization. 24 January 2020.
Retrieved 4JANUARY, 2021.